The reverse acquisition company Hunter Capital RTO1 states that Danish biotech company Resother Pharma has completed a bridge financing of approximately SEK 14.8 million at a pre-money valuation of approximately SEK 225 million ahead of the planned listing in September.The company also states that results from the phase 2a study are expected in September and that recruitment to the study has been completed.Earlier this year, Hunter Capital RTO1 signed a letter of intent for a reverse acquisition of Resother Pharma. The parties continue work to complete the planned transaction in accordance with the letter of intent.